Nike's latest hire isn't a retail veteran or a company insider like CEO Elliott Hill. Rather, he comes from the pharmaceutical industry.

The activewear brand late Tuesday named David Denton as its next chief financial officer, effective Aug. 17. Denton succeeds Matthew Friend, who will stay on through Sept. 4 "to support an orderly transition," Nike said.

Denton most recently served as CFO and executive vice president at Pfizer, a title he held since May 2022. Earlier in his career, Denton spent two decades at CVS Health, overseeing the company's transition from a corner drugstore chain to a healthcare giant through its acquisition of pharmacy-benefits manager Caremark in 2007.

His background contrasts with company veterans like Chief Executive Hill, who started at Nike as an intern in 1988, and its former CFO, who joined in 2009.

Hill described Denton as "a proven public-company CFO" in a press release, adding that his experience would help Nike execute its priorities "with consistency" and build on its ongoing turnaround.

Denton echoed that enthusiasm. "Like so many people, I've long admired Nike," he wrote in a LinkedIn post. "This is an important moment for the company, and I am honored to have the opportunity to contribute to its future."

Denton will join Nike with a $1.45 million annual base salary, along with a yearly target bonus of 120% of his salary and an annual target long-term incentive award of $11.5 million. To offset lost compensation from Pfizer, Nike will also pay him a one-time cash sign-on bonus of $7.25 million.

Denton's appointment was perhaps the most salient detail in Nike's announcement on Tuesday. The company separately said its fiscal fourth-quarter guidance would be generally in line with its prior outlook, save for an unexpected "benefit from tariff refunds."

Nike previously guided for sales to fall between 2% and 4% in the current quarter, including a 20% drop in China. The retailer is slated to post quarterly results on June 30.

Nike stock was up 0.5% at $42.60 in premarket trading Wednesday.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

June 24, 2026 08:09 ET (12:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.